OBJECTIVE：To systematically review the efficacy and safety of Aidi injection combined with paclitaxel and cisplatin in the treatment of advanced non-small cell lung cancer （NSCLC）， and provide evidence-based reference for clinic. METHODS： Retrieved from PubMed， EMBase， Cochrane Library， CJFD，VIP and Wanfang Database，randomized controlled trials （RCT） about the efficacy and safety of Aidi injection （test group） based on paclitaxel combined with cisplatin （control group） in the treatment of NSCLC were collected. Meta-analysis was performed by using Rev Man 5.2 software after data extraction and quality evaluation with Cochrane systematic reviewer manual 5.1.0. RESULTS： Totally 16 RCT were included， involving 1 025 patients. Results of Meta-analysis showed that， the effective rate [RR＝1.34，95％CI（1.17，1.52），P＜0.001] and improvement rate of life quality[RR＝1.69，95％CI（1.45，1.97），P＜0.001] in test group were significantly higher than control group； the incidences of grade Ⅱ or above nausea and vomiting [RR＝0.49，95％CI（0.38，0.63），P＜0.001]，grade Ⅱ or above leukopenia[RR＝0.48，95％CI（0.38，0.62），P＜0.001] and grade Ⅱor above thrombocytopenia [RR＝0.45，95％CI（0.29，0.69），P＜0.001] were significantly lower than control group， the differences were statistically significant. CONCLUSIONS： Aidi injection combined with paclitaxel and cisplatin can significantly improve efficacy of NSCLC， improve life quality， with good safety.